VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Madrigal Pharmaceuticals Executive Compensation (FY25)

MDGL · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Bill Sibold
Median of the other named officers
$6,085,089
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 17, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Madrigal Pharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 17, 2026
13 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Madrigal Pharmaceuticals brief$500Get the executive brief
Velarion Intel, one year, every company
363 figures on this page: 353 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Bill Sibold: $12,214,250 → $19,206,341 (57.2% higher)
Say-on-pay support: 98.9% → 97.1% (1.8 points lower)
CEO pay ratio: 38:1 → 47:1 (23.7% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Madrigal Pharmaceuticals' chief executive and what were they paid?
Bill Sibold was paid $19,206,341 in total compensation as President and Chief Executive Officer for fiscal 2025. Sibold's total moved 57.2% higher from the $12,214,250 reported for fiscal 2024.
What was Madrigal Pharmaceuticals' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 97.1% of votes cast for or against in favor at the meeting held June 17, 2026.
Which companies are in Madrigal Pharmaceuticals' peer group?
The disclosed peer group includes Alnylam Pharmaceuticals, Apellis Pharmaceuticals, CRISPR Therapeutics AG, Cytokinetics and Exelixis, among others.
What is Madrigal Pharmaceuticals' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 47:1, against median employee compensation of $403,403.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Paul Friedman
Former Chief Executive Officer
◇——◇◇——◇
Brian Lynch
Former Senior Vice President and General Counsel
◇——◇◇—◇◇
Rebecca Taub
Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer
◇——◇◇——◇
Remy Sukhija
Former Senior Vice President, Chief Commercial Officer
◇——◇◇—◇◇
Alex Howarth
Former Senior Vice President and Chief Financial Officer
◇——◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bill Sibold
President and Chief Executive Officer
◇◇◇—◇——◇
Paul Friedman
Former Chief Executive Officer
Departed during or after this year
◇—◇———◇◇
Remy Sukhija
Former Senior Vice President, Chief Commercial Officer
Departed during or after this year
◇—◇———◇◇
Rebecca Taub
Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer
◇—◇—◇——◇
Brian Lynch
Former Senior Vice President and General Counsel
◇—◇—◇—◇◇
Alex Howarth
Former Senior Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Carole Huntsman
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bill Sibold
President and Chief Executive Officer
◇—◇◇◇—◇◇
Mardi Dier
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Rebecca Taub
Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer
Departed during or after this year
◇—◇◇◇—◇◇
Alex Howarth
Former Senior Vice President and Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Shannon Kelley
Executive Vice President and Chief Legal Counsel
◇—◇◇◇—◇◇
Brian Lynch
Former Senior Vice President and General Counsel
Departed during or after this year
◇—◇◇——◇◇
Carole Huntsman
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bill Sibold
President and Chief Executive Officer
◇—◇◇◇—◇◇
David Soergel
Executive Vice President and Chief Medical Officer
◇◇◇◇◇——◇
Rebecca Taub
Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer
Departed during or after this year
◇—◇◇◇——◇
Mardi Dier
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Carole Huntsman
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Shannon Kelley
Executive Vice President and Chief Legal Counsel
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Bill SiboldPSU◇◇◇—◇—◇
Bill SiboldRSU◇——◇——◇
Bill SiboldOPTION◇——◇—◇◇
Carole HuntsmanPSU◇◇◇—◇—◇
Carole HuntsmanRSU◇——◇——◇
Carole HuntsmanOPTION◇——◇—◇◇
David SoergelPSU◇◇◇—◇—◇
David SoergelRSU◇——◇——◇
David SoergelOPTION◇——◇—◇◇
Mardi DierPSU◇◇◇—◇—◇
Mardi DierRSU◇——◇——◇
Mardi DierOPTION◇——◇—◇◇
Rebecca TaubPSU◇◇◇—◇—◇
Rebecca TaubRSU◇——◇——◇
Rebecca TaubOPTION◇——◇—◇◇
Shannon KelleyPSU◇◇◇—◇—◇
Shannon KelleyRSU◇——◇——◇
Shannon KelleyOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Bill SiboldPSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇3/5/2035
RSU◇◇——
Option◇—◇1/23/2031
RSU◇◇——
Mardi DierPSU◇◇——
PSU◇◇——
Option◇—◇3/1/2031
RSU◇◇——
Option◇—◇3/5/2035
RSU◇◇——
David SoergelPSU◇◇——
Option◇—◇5/15/2035
RSU◇◇——
Rebecca TaubPSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇3/5/2035
Option◇—◇1/23/2031
RSU◇◇——
RSU◇◇——
Option◇—◇2/22/2032
Carole HuntsmanPSU◇◇——
PSU◇◇——
Option◇—◇3/5/2035
Option◇—◇11/20/2033
RSU◇◇——
RSU◇◇——
Option◇—◇1/23/2031
RSU◇◇——
Shannon KelleyPSU◇◇——
Option◇—◇8/15/2031
Option◇—◇3/5/2035
RSU◇◇——
RSU◇◇——
Option◇—◇1/16/2031
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jacqualyn A. Fouse, Ph.D
◇◇————◇
Daniel J. Brennan
◇◇————◇
Julian C. Baker
Board chair
◇◇————◇
Richard S. Levy, M.D
◇◇————◇
Raymond Cheong, M.D., Ph.D
◇◇————◇
Kenneth M. Bate
◇◇————◇
James M. Daly
◇◇————◇
Paul A. Friedman, M.D
◇◇————◇
Fred B. Craves, Ph.D
◇—————◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as RSUs and stock options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alnylam Pharmaceuticals ALNY
  • Apellis Pharmaceuticals APLS
  • CRISPR Therapeutics AG CRSP
  • Cytokinetics CYTK
  • Exelixis EXEL
  • Halozyme Therapeutics HALO
  • Insmed INSM
  • Intra-Cellular Therapies ITCI
  • Ionis Pharmaceuticals IONS
  • Neurocrine Biosciences NBIX
  • Roivant Sciences ROIV
  • Sarepta Therapeutics SRPT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 17, 2026=◇◇◇
2024June 20, 2025=◇◇◇
2023June 25, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 15, 2022=◇◇◇
2020June 17, 2021=◇◇◇
2019June 17, 2020=◇◇◇
2018June 27, 2019=◇◇◇
2017June 19, 2018=◇◇◇
2016June 29, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Bill Sibold (President and Chief Executive Officer), FY2025 total compensation $19,206,341 (base salary $918,531) [exec_comp, SEC accession 0001308179-26-000352, filed 2026-04-28]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Madrigal Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Madrigal Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Madrigal Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Madrigal Pharmaceuticals' disclosed peer group is defensible, who names Madrigal Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
363 figures on this page: 353 cited to the filing that reported them, 10 calculated from figures it prints.
353 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001104659-26-075130
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001308179-26-000352
    CEO Pay Ratio · Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year End · and 1 more section
  3. 0001628280-25-032358
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001104659-25-041254
    Summary Compensation Table
  5. 0001193125-24-170634
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-24-122657
    Summary Compensation Table
  7. 0001193125-23-169187
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-22-176256
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001193125-21-194456
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-20-171925
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-19-188020
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001104659-18-041808
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001047469-17-004401
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Madrigal Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/MDGL (accessed 2026).
Short form: data: Velarion

The Madrigal Pharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Madrigal Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Madrigal Pharmaceuticals discloses

The companies named in MDGL's own disclosed peer group.

Alnylam PharmaceuticalsApellis PharmaceuticalsCRISPR Therapeutics AGCytokineticsExelixisHalozyme TherapeuticsInsmedIntra-Cellular TherapiesIonis PharmaceuticalsNeurocrine BiosciencesRoivant SciencesSarepta Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy